Millions of people take antibiotics to get better, but a certain group of the drugs comes with serious side effect warnings.
Click here for the petitions.
For more information, click here.
"Patient safety is our first priority at Bayer. We care deeply about patients and take the safety of our medicines very seriously. Cipro (ciprofloxacin) has been in the U.S. market since 1987, with extensive clinical experience and a proven safety profile, and is to be used in accordance with the label, which includes a description of its respective approved indications and appropriate mode of administration, as well as contraindications, adverse reactions, interactions, warnings and precautions. Bayer maintains accurate product labels that share information about the benefits and risks associated with Cipro use. We report all adverse events we learn about to the U.S. Food and Drug Administration (FDA) and actively monitor such reports including ones raised in the Citizen's Petition." - Bayer Corporation
"Our first priority is the well-being of the people who use our medicines. We are aware of the citizen petition and are evaluating it. LEVAQUIN (levofloxacin) is part of the important fluoroquinolone class of anti-infective prescription medications that have been used for more than 20 years to treat infections, including those that may be serious or life threatening. All medicines, including LEVAQUIN, have both benefits and risks. We continually collect and monitor information on the safety and effectiveness of all our medicines, and, in cooperation with the US FDA and other health authorities, we incorporate new data into our product labels so doctors and patients can make informed decisions. Ever since it was first approved by the FDA in 1996, the LEVAQUIN label has provided information to physicians on the risks and benefits associated with the medication, including warnings and precautions. Since 2004, the LEVAQUIN label has informed physicians and patients about possible side effects related to peripheral neuropathy. "